Utility of an Immunotherapy Trial in Evaluating Patients with Presumed Autoimmune Epilepsy
Neurol 82:1578-1586, Toledano, M.,et al, 2014
Intravenous IgG in Guillain-Barre Syndrome
BMJ 313:376-377, Hughes,R.A.C., 1996
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Clinicopathologic conference, Malignant Mixed Germ-Cell Tumor and Anti-NMDA Receptor Encephalitis
NEJM 303:488-496, Case 22-2025, 2025
Clinicopathological Conference, Glutamic Acid Decarborylase 65 Autoantibody-Associated Stiff-Person Syndrome
NEJM 390:1712-1719, Case 14-2024, 2024
Vaccine-Induced Thrombocytopenia with Severe Headache
NEJM 385:doi:10.1056/NEJMc2112974, Salih, F.,et al, 2021
An 82-year-old man with Worsening Gait
Neurol 89:e246-e252, Chew, S.,et al, 2017
Paraparetic Guillain-Barre Syndrome
Neurol 82:1984-1989, Van Den Berg, B.,et al, 2014
Stiff-Man Syndrome and Variants
Arch Neurol 69:230-238, McKeon,A.,et al, 2012
Clinical Reasoning: A 34-year-old man with recurrent limb weakness
Neurol 77:e68-e72, Karam, C.,et al, 2011
Diagnosis and Management of the Antiphospholipid Syndrome
BMJ 340:1125-1132, Cohen,D., et al, 2010
Guillain-Barre Syndrome
BMJ 337:227-231, Winer,J.B., 2008
Clinicopath Conf., Multifocal Motor Neuropathy With Conduction Block
NEJM 357: 2707-2715, Case 40-2007, 2007
Human Botulism Immune Globulin for the Treatment of Infant Botulism
NEJM 354:462-471, Arnon,S.S.,et al, 2006
Potassium Channel Antibody-Associated Encephalopathy: A Potentially Immunotherapy-Responsive Form of Limbic Encepahlitis
Brain 127:701-712, Vincent,A.,et al, 2004
The Therapeutic Dilemma of Inclusion Body Myositis
Neurol 48:567-568, Barohn,R.J., 1997
Multifocal Motor Neuropathy
JNNP 60:599-603, Nobile-Orazio,E., 1996
Multifocal Motor Neuropathy with Conduction Block:A Study of 24 Patients
JNNP 59:38-44, Bouche,P.,et al, 1995
Multifocal Demyelinating Motor Neuropathy:Cranial Nerve Involvement and Immunoglobulin Therapy
Neurol 42:506-509, Kaji,R.,et al, 1992
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Myasthenic Crisis Demanding Mechanical Ventilation
Neurol 94:e299-e313, Neumann, B.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Intravenous Immune Globulin: Adverse Effects
UptoDate June, Perez, E.E. & Silvergleid, A.J., 2017
Reversible Cerebral Vasoconstriction Syndromes
MedLink Aug, Singhai, A.B. & Levine, S.R., 2015
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Guillain-Barre Syndrome
NEJM 366:2294-2304, Yuki, N. & Hartung, H.P., 2012
Comparison of IVIg and PLEX in patients with myasthenia gravis
Neurol 76:2017-2023, Barth, D.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Comparative Analysis of Therapeutic Options Used for Myasthenia Gravis
Ann Neurol 68:797-805, Mandawat,A.,et al, 2010
Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009
Acute Encephalopathy Associated with Intravenous Immunoglobulin Therapy
AJNR 26:2311-2315, Wada,A.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Arterial Thrombosis Induced by IVIg and Its Treatment with tPA
Neurol 60:1825-1826,1736, Okuda,D.,et al, 2003
Treatment of Autoimmune Myasthenia Gravis
Neurol 61:1652-1661, Richman,D.P. & Agius,M.A., 2003
Intravenous Immunoglobulin in Neurological Disease: A specialist Review
JNNP 72:440-448, Wiles,C.M.,et al, 2002
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Pompholyx (Vesicular Eczema) After IV Immunoglobulin Therapy for Neurologic Disease
Neurol 53:1154-1155, Iannaccone,S.,et al, 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Neurologic Complic of Treat of Childhood Acute Immune Thrombocytopenic Purpura with IVIG
J Pediatr 130:281-283, Kattamis,A.C.,et al, 1997
Intravenous Immune Globulin Therapy for Neurologic Diseases
Ann Int Med 126:721-730, Dalakas,M.C., 1997
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Reversible Encephalopathy with Cerebral Vasospasm in a Guillain-Barre Syndrome Patient Treated with Intravenous Immunoglobulin
Neurol 46:250-251, Voltz,R.,et al, 1996
Pilot Trial of Immunoglobulin Versus Plasma Exchange in Patients with Guillain-Barre Syndrome
Neurol 46:100-103, Bril,V.,et al, 1996
Complications of Intravenous Gammaglobulin in Neuromuscular and other Disease
Muscle & Nerve 19:388-391996., Bertorini,T.E.,et al, 1996
Complications of Intravenous Immune Globulin Treatment in Neurologic Disease
Neurol 47:674-677, Brannagan III,T.H.,et al, 1996
High-Dose Intravenous Immunoglobulin and Serum Viscosity:Risk of Precipitating Thromboembolic Events
Neurol 44:223-226, Dalakas,M., 1994
Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994